PDCD1 and non-small cell lung carcinoma: Moreover, when considering patients with NSCLC who have undergone prior treatment, a decreased rate of disease progression is more frequently observed in response to PD-1/PD-L1 inhibitors, as opposed to conventional chemotherapy.